Background: Efavirenz (EFV) has variable bioavailability and induces neurocognitive side effects, including anxiety. Recently we reported an EFV solid drug nanoparticle (SDN) formulation with pharmacological benefits. Here we investigated neurocognitive disturbances in rats using the elevated plus maze (EPM) after administration of a conventional or SDN formulation. In this model, anxiety is typically demonstrated by time spent in the open arms versus the closed arms, with greater anxiety linked to less time on the open arms. Methodology: Male Wistar rats were administered EFV (10mg/kg, 0.5% methylcellulose), SDN (10mg/kg) or vehicle control by oral gavage once daily for 5 weeks. Rats were placed in the EPM for 5 minutes weekly. Behavior was videotaped and analyzed using Ethowatcher software. Data were collected on number of entrances into the open and closed arms and time spent in the open arm, closed arm and central square (expressed as percentage of total time on EPM). Statistical analysis was performed by Mann-Whitney U test and significance was defined as P <0.05. All data are given as median [IQR]. Results: No differences in behavior were observed in week 1. In week 2, the percentage of time spent on the central platform was significantly increased in the EFV group (60% [51-65%]) compared to SDN (44% [25-50%]) and control (47% [34-57%] with P = 0.03 and P = 0.91 for EFV and SDN versus control, respectively. The EFV group spent less time in the closed arm than the SDN group but this was not statistically significant. In week 3 differences in time spent on the central platform were again observed (EFV 65% [48-71%], SDN 31% [25-42%], control 46% [28-52%], with P = 0.01 and P =0.28 for EFV and SDN versus control, respectively. Significant differences in the time spent in the closed arm were also observed (EFV 21% [13-46%], SDN 66% [47-75%], control 43% [33-71%]) with P = 0.005 and P = 0.631 for EFV and SDN versus control, respectively. Similarly in week 4, time spent by the EFV group on the closed arms was lower (EFV 34% [28-42%], control 61% [IQR 46-72%]; P = 0.005) and time on the central platform was higher (EFV 51% [46-57], control 30%, [26-42%]; P = 0.001). No statistically significant differences in behavior between any groups were observed in week 5. Conclusions: Our experiment did not fully replicate EFV anxiogenic effects previously reported using the EPM, but did show clear behavioral effects indicative of CNS activity. Notably, a tendency of EFV to increase time spent on the central platform may be indicative of anxiogenesis. By contrast, the SDN did not consistently affect behavior in a manner that would indicate anxiogenic activity. We interpret these data as indicating the SDN may have reduced potential to induce neurocognitive disturbance, either acutely or after long-term administration.